论文部分内容阅读
为了解卡介苗（ＢＣＧ）与α－干扰素联合应用膀胱灌注预防膀胱癌术后复发的疗效，将７２例膀胱癌随机分为两组：一组用ＢＣＧ７５ｍｇ＋α－干扰素６０万ｕ，另一组单用ＢＣＧ７５ｍｇ膀胱内灌注。随访６～７２个月，平均３８．６个月，肿瘤复发者ＢＣＧ＋α－干扰素组２例（５．６％），ＢＣＧ组９例（２５％），两组比较有显著性差异（Ｐ＜０．０５）。结果表明：ＢＣＧ与α－干扰素联合应用能更有效地预防膀胱癌术后复发
To understand the effect of combined use of BCG and α-interferon for the prevention of postoperative recurrence of bladder cancer, 72 cases of bladder cancer were randomly divided into two groups: one group was treated with BCG75mg+α-interferon 600,000u, and the other group was only BCG75mg intravesical instillation. The follow-up ranged from 6 to 72 months (mean 38.6 months). Tumor recurrence occurred in 2 patients (5.6%) in the BCG+α-interferon group and 9 patients (25%) in the BCG group. There was a significant difference between the two groups (P< 0.05). The results showed that the combination of BCG and α-interferon can prevent bladder cancer recurrence more effectively